<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="207">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431052</url>
  </required_header>
  <id_info>
    <org_study_id>DRM01B-ACN02</org_study_id>
    <nct_id>NCT02431052</nct_id>
  </id_info>
  <brief_title>A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Vehicle-controlled, Dose-ranging Study of DRM01B Topical Gel in Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermira, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the safety and efficacy DRM01 Topical Gel
      compared to vehicle in patients with acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Absolute change in lesion counts (inflammatory and non-inflammatory) from baseline and a minimum 2-grade improvement from baseline in Investigator's Global Assessment (IGA) score</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percent change from baseline in inflammatory and non-inflammatory lesion counts</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRM01</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRM01</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRM01</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRM01</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_label>Treatment E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Male or non-pregnant, non-lactating females.

          -  Age ≥ 18 years.

          -  Clinical diagnosis of facial acne vulgaris defined as:

          -  At least 20 inflammatory lesions

          -  At least 20 non-inflammatory lesions

          -  Investigator Global Assessment of 3 or greater.

        Exclusion Criteria:

          -  Active cystic acne or acne congoblata, acne fulminans, and secondary acne.

          -  Two or more active nodulocystic lesions.

          -  Screening clinical chemistry or hematology laboratory value that is considered
             clinically significant, in the opinion of the Investigator.

          -  Abnormal findings on screening ECG, deemed clinically significant, by the
             Investigator.

          -  Subjects who are actively participating in an experimental therapy study or who have
             received experimental therapy within 30 days or 5 half-lives (whichever is longer) of
             the Baseline visit.

          -  Subjects who are a poor medical risk because of other systemic diseases or active
             uncontrolled infections, in the opinion of the investigator.

          -  Treatment with over-the-counter topical medications for the treatment of acne
             vulgaris including benzoyl peroxide, topical anti-inflammatory medications,
             corticosteroids, α-hydroxy/glycolic acid on the face within 2 weeks prior to
             Baseline.

          -  Treatment with systemic corticosteroids (use of intranasal and inhaled
             corticosteroids allowed for seasonal allergies and asthma) within 4 weeks prior to
             Baseline.

          -  Treatment with systemic antibiotics or systemic anti-acne drugs or systemic
             anti-inflammatory drugs within 4 weeks prior to Baseline.

          -  Prescription topical retinoid use on the face within 4 weeks of Baseline (e.g.,
             tretinoin, tazarotene, adapalene).

          -  Treatment with a new hormonal therapy or dose change to existing hormonal therapy
             within 12 weeks prior to Baseline. Dose and frequency of use of any hormonal therapy
             started more than 12 weeks prior to Baseline must remain unchanged throughout the
             study. Hormonal therapies include, but are not limited to, estrogenic and
             progestational agents such as birth control pills.

          -  Prior use of androgen receptor blockers (such as spironolactone or flutamide).

          -  Oral retinoid use (e.g., isotretinoin) within 12 months prior to Baseline or vitamin
             A supplements greater than 10,000 units/day within 6 months of Baseline.

          -  Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 8
             weeks or during the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth Zib</last_name>
    <role>Study Director</role>
    <affiliation>Dermira, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Welch, MPH, CCRC</last_name>
      <phone>251-414-1984</phone>
      <email>kathyw@ccr-research.com</email>
    </contact>
    <investigator>
      <last_name>Aldo Trovato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tory Sullivan MD PA</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Chockley</last_name>
      <phone>305-652-8600</phone>
      <email>achockley@leavittmgt.com</email>
    </contact>
    <investigator>
      <last_name>Tory P Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MOORE Clinical Research, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Schofield</last_name>
      <phone>813-948-7550</phone>
      <phone_ext>303</phone_ext>
      <email>info@mooreclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Susan M Barker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Kitten</last_name>
      <phone>502-451-9000</phone>
      <email>wedoderm@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Leon H Kircik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lawrence J. Green, MD, LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan A Collich, CCRP</last_name>
      <phone>301-610-0063</phone>
      <email>scollich@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Lawrence J Green, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Center for Skin Care Research</name>
      <address>
        <city>Clinton, TWP</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacey Yang</last_name>
      <phone>865-251-9963</phone>
      <email>clinicaltrials@skincareresearch.com</email>
    </contact>
    <investigator>
      <last_name>Daniel M Stewart, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detriot</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Stein Gold, MD</last_name>
      <phone>313-916-1984</phone>
      <email>lstein1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Linda Stein Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allie Horita</last_name>
      <phone>763-502-2941</phone>
      <email>ahorita@associatedskincare.com</email>
    </contact>
    <investigator>
      <last_name>Steven E Kempers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Las Vegas Skin and Cancer Clinics</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Tiglao</last_name>
      <phone>702-990-4800</phone>
      <phone_ext>129</phone_ext>
      <email>etiglao@lvscc.com</email>
    </contact>
    <investigator>
      <last_name>Del Rosso Q James, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlenny Carbajal</last_name>
      <phone>505-247-4220</phone>
      <email>mcarbajal@abqdermtrials.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Tschen, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Search of Rochester, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Forster, LPN,BS,CCRC</last_name>
      <phone>585-697-1818</phone>
      <email>dforster@dermrochester.com</email>
    </contact>
    <investigator>
      <last_name>John H Tu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe Draelos, MD</last_name>
      <phone>336-841-2040</phone>
      <email>zdraelos@northstate.net</email>
    </contact>
    <investigator>
      <last_name>Zoe D Draelos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Skin Wellness Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Butcher, BS</last_name>
      <phone>865-293-4983</phone>
      <email>jbutcher.swc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kimberly Grande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Garner, LVN, CCRC</last_name>
      <phone>512-349-9889</phone>
      <email>dgarner@dermresearch.net</email>
    </contact>
    <investigator>
      <last_name>Janet DuBois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc.</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Scott</last_name>
      <phone>979-774-5933</phone>
      <email>jscott@js-studies.com</email>
    </contact>
    <investigator>
      <last_name>Terry M Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies, LTD. LLP</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Harris</last_name>
      <phone>713-528-8818</phone>
      <phone_ext>1208</phone_ext>
      <email>kharris@ccstexas.com</email>
    </contact>
    <investigator>
      <last_name>Stephen K Tyring, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce &amp; Associates, PA. The Center for Skin Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Herod</last_name>
      <phone>713-985-0210</phone>
      <phone_ext>156</phone_ext>
      <email>aherod@sba-skincare.com</email>
    </contact>
    <investigator>
      <last_name>Suzanne Bruce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce &amp; Associates, PA. The Center for Skin Research</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Piconal</last_name>
      <phone>713-985-0210</phone>
      <phone_ext>152</phone_ext>
      <email>mpiconal@sba-skincare.com</email>
    </contact>
    <contact_backup>
      <last_name>Valarie Barbosa</last_name>
      <phone>713-985-0210</phone>
      <phone_ext>117</phone_ext>
      <email>vbarbosa@sba-skincare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Syed O Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Lewis</last_name>
      <phone>512-279-2545</phone>
      <email>patricia@atxderm.com</email>
    </contact>
    <investigator>
      <last_name>Edward L Lain, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Oranday, LVN, CCRC</last_name>
      <phone>210-614-5557</phone>
      <email>toranday@progclin.com</email>
    </contact>
    <investigator>
      <last_name>Mark S. Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Davenport, RA</last_name>
      <phone>801-269-0135</phone>
      <email>kim@dermatologyresearch.net</email>
    </contact>
    <investigator>
      <last_name>Leonard J. Swinyer, MD FAAD CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Education &amp; Research Foundation, Inc.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Doyle</last_name>
      <phone>434-847-8400</phone>
      <email>juliedoyle@educationandresearch.com</email>
    </contact>
    <investigator>
      <last_name>David C Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dayln Boehm</last_name>
      <phone>509-343-3710</phone>
      <email>research@premierclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>William P Werschler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kirk Barber Research</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2G1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arjuni Seevaratnam</last_name>
      <phone>403-299-5821</phone>
      <email>arjuni@kirkbarber.ca</email>
    </contact>
    <investigator>
      <last_name>Kirk Barber, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Enverus Medical Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reena Tut-Parhar</last_name>
      <phone>604-495-8278</phone>
      <email>reena@enverusmedical.com</email>
    </contact>
    <investigator>
      <last_name>Lorne E Albrecht, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lynderm Research</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles W Lynde, BSc,MD,FRCPC</last_name>
      <phone>905-471-8011</phone>
      <email>derma@lynderma.com</email>
    </contact>
    <investigator>
      <last_name>Charles W Lynde, BSc,MD,FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research, Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Moore</last_name>
      <phone>519-971-7693</phone>
      <email>shannon.moore@bellnet.ca</email>
    </contact>
    <investigator>
      <last_name>Jerry Tan, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Maari, MD</last_name>
      <phone>514-521-3111</phone>
      <email>cmaari@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Catherine Maari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermetologique du Quebec Metropolitain (CRDQ)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josee Dumas</last_name>
      <phone>418-650-5161</phone>
      <email>crdq@bellnet.ca</email>
    </contact>
    <investigator>
      <last_name>Yves Poulin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 12, 2015</lastchanged_date>
  <firstreceived_date>April 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
